Target Name: SPARC
NCBI ID: G6678
Review Report on SPARC Target / Biomarker Content of Review Report on SPARC Target / Biomarker
SPARC
Other Name(s): Secreted protein acidic and cysteine rich, transcript variant 3 | Ad158 | secreted protein acidic and cysteine rich | ON | SPARC (isoform 1) | Secreted protein acidic and cysteine rich, transcript variant 1 | Leucine-rich repeat-containing protein 8C | Factor for adipocyte differentiation 158 | basement-membrane protein 40 | Secreted protein, acidic, cysteine-rich (osteonectin) | Secreted protein, acidic, cysteine-rich | OI17 | Basement membrane protein BM-40 | Osteonectin | secreted protein, acidic, cysteine-rich (osteonectin) | SPARC variant 1 | SPARC variant 2 | BM-40 | SPARC variant 3 | SPRC_HUMAN | Secreted protein acidic and rich in cysteine | SPARC (isoform 3) | Basement-membrane protein 40 | ONT | Secreted protein acidic and cysteine rich, transcript variant 2 | SPARC (isoform 2)

SPARC: A Potential Drug Target for Neurodegenerative Diseases

SPARC (Secured Protein Acidic and Cysteine-rich) is a protein that is found in various cell types in the human body. It is made up of four amino acids: cysteine, glutamic acid, aspartic acid, and glycine. Cysteine is the most abundant of these amino acids, and it is the amino acid that gives SPARC its name.

SPARC has been identified as a potential drug target in the field of neurodegenerative diseases. Its unique structure and the way it interacts with other proteins make it an attractive target for drug developers.

SPARC is involved in many different cellular processes in the body, including the regulation of enzyme activity and the detoxification of harmful substances. It is also involved in the formation of new blood vessels, which is important for the delivery of oxygen and nutrients to the brain.

SPARC has also been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It is thought to do this by participating in the breakdown of damaged cells and the formation of new ones, as well as by contributing to the development of neurodegenerate plaques.

SPARC is also a good candidate as a biomarker for monitoring the progression of neurodegenerative diseases. Its level can be measured in the blood, which makes it a non-invasive test for monitoring the effects of a drug on the brain. This can be important for identifying potential drug targets and for understanding the underlying mechanisms of neurodegenerative diseases.

In conclusion, SPARC is a protein that is worth investigating as a drug target or biomarker. Its unique structure and the way it interacts with other proteins make it an attractive target for drug developers. Further research is needed to understand its role in the development and progression of neurodegenerative diseases, as well as its potential as a biomarker for these conditions.

Protein Name: Secreted Protein Acidic And Cysteine Rich

Functions: Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity

The "SPARC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPARC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SPARCL1 | SPART | SPART-AS1 | SPAST | SPATA1 | SPATA12 | SPATA13 | SPATA13-AS1 | SPATA16 | SPATA17 | SPATA18 | SPATA19 | SPATA2 | SPATA20 | SPATA20P1 | SPATA21 | SPATA22 | SPATA24 | SPATA25 | SPATA2L | SPATA3 | SPATA3-AS1 | SPATA31A1 | SPATA31A2 | SPATA31A3 | SPATA31A5 | SPATA31A6 | SPATA31A7 | SPATA31C1 | SPATA31C2 | SPATA31D1 | SPATA31D3 | SPATA31E1 | SPATA32 | SPATA33 | SPATA4 | SPATA41 | SPATA42 | SPATA45 | SPATA46 | SPATA48 | SPATA5 | SPATA5L1 | SPATA6 | SPATA6L | SPATA7 | SPATA8 | SPATA8-AS1 | SPATA9 | SPATC1 | SPATC1L | SPATS1 | SPATS2 | SPATS2L | SPC24 | SPC25 | SPCS1 | SPCS2 | SPCS2P4 | SPCS3 | SPDEF | SPDL1 | SPDYA | SPDYC | SPDYE1 | SPDYE18 | SPDYE2 | SPDYE21 | SPDYE2B | SPDYE3 | SPDYE4 | SPDYE5 | SPDYE6 | SPDYE7P | SPDYE8 | SPDYE9 | SPECC1 | SPECC1L | SPECC1L-ADORA2A | SPEF1 | SPEF2 | SPEG | SPEM1 | SPEM2 | SPEN | SPEN-AS1 | SPESP1 | SPG11 | SPG21 | SPG7 | SPHAR | Sphingolipid delta(4)-desaturase | Sphingomyelin phosphodiesterase | Sphingomyelin synthase | Sphingosine kinase | SPHK1 | SPHK2 | SPHKAP | SPI1 | SPIB